Hemispherx BioPharma, Inc Share Price Nyse
Equities
US42366C3016
Biotechnology & Medical Research
Sales 2024 * | 113K 9.46M | Sales 2025 * | 1.78M 149M | Capitalization | 19.94M 1.66B |
---|---|---|---|---|---|
Net income 2024 * | -24M -2B | Net income 2025 * | -25M -2.09B | EV / Sales 2024 * | 176 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 11.2 x |
P/E ratio 2024 * |
-0.82
x | P/E ratio 2025 * |
-0.88
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 04/22/04 |
Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 28/23/28 |
William Mitchell
CHM | Chairman | 89 | 01/98/01 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 17/08/17 |
1st Jan change | Capi. | |
---|---|---|
+8.08% | 113B | |
+10.28% | 106B | |
+0.41% | 22.27B | |
-12.09% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.69% | 17.24B | |
+7.48% | 14.29B | |
+36.89% | 12.52B |